Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon alpha nasal drops for COVID-19 prevention in medical staff
NCT04320238Phase 3Unknown
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Jan 2020
- Primary completion
- May 2020
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, open-label trial of Antiviral Oral Spray in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: new-onset COVID-19 at 6 weeks. Status: unknown.
02
Drugs
Antiviral Oral Spray
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04320238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04320238.